cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.8035670
title: Patient 3 CT

description: CTs and MRIs were both acquired under radiotherapy immobilization protocols with patients in the treatment position.<br>CT scans were acquired on one of four machine models (LightSpeed RT16, GE Medical Systems, Waukesha, WI, USA; Brilliance 64 or Brilliance Big Bore, Philips Healthcare, Cambridge, MA, USA; SOMATOM Definition Edge, Siemens, Washington D.C., USA) using x-ray tube currents between 208 – 434 mA at 120 kVp. All scans have slice thicknesses of either 2.5 or 3 mm, with 2.5 or 3 mm of space between slices. Sections are displayed in 512 x 512 pixel matrices and were reconstructed in diameters between 500 – 600 mm. <br>MRI scans were acquired in one of two machine models (Discovery MR750, GE Medical Systems, Waukesha, WI, USA; Ingenia, Philips Healthcare, Cambridge, MA, USA) in 3 Tesla magnetic fields with echo times between 97.72 – 101.82 milliseconds. All scans have slice thicknesses of 2.5 mm, with 2.5 or 4 mm of space between slices. Sections are displayed in 512 x 512 pixel matrices and were reconstructed in 256 mm diameters.
DOI: 10.6084/m9.figshare.8035673
title: Patient 4 MRI

description: CTs and MRIs were both acquired under radiotherapy immobilization protocols with patients in the treatment position.<br>CT scans were acquired on one of four machine models (LightSpeed RT16, GE Medical Systems, Waukesha, WI, USA; Brilliance 64 or Brilliance Big Bore, Philips Healthcare, Cambridge, MA, USA; SOMATOM Definition Edge, Siemens, Washington D.C., USA) using x-ray tube currents between 208 – 434 mA at 120 kVp. All scans have slice thicknesses of either 2.5 or 3 mm, with 2.5 or 3 mm of space between slices. Sections are displayed in 512 x 512 pixel matrices and were reconstructed in diameters between 500 – 600 mm. <br>MRI scans were acquired in one of two machine models (Discovery MR750, GE Medical Systems, Waukesha, WI, USA; Ingenia, Philips Healthcare, Cambridge, MA, USA) in 3 Tesla magnetic fields with echo times between 97.72 – 101.82 milliseconds. All scans have slice thicknesses of 2.5 mm, with 2.5 or 4 mm of space between slices. Sections are displayed in 512 x 512 pixel matrices and were reconstructed in 256 mm diameters.
DOI: 10.6084/m9.figshare.8035673.v1
title: Patient 4 MRI

description: CTs and MRIs were both acquired under radiotherapy immobilization protocols with patients in the treatment position.<br>CT scans were acquired on one of four machine models (LightSpeed RT16, GE Medical Systems, Waukesha, WI, USA; Brilliance 64 or Brilliance Big Bore, Philips Healthcare, Cambridge, MA, USA; SOMATOM Definition Edge, Siemens, Washington D.C., USA) using x-ray tube currents between 208 – 434 mA at 120 kVp. All scans have slice thicknesses of either 2.5 or 3 mm, with 2.5 or 3 mm of space between slices. Sections are displayed in 512 x 512 pixel matrices and were reconstructed in diameters between 500 – 600 mm. <br>MRI scans were acquired in one of two machine models (Discovery MR750, GE Medical Systems, Waukesha, WI, USA; Ingenia, Philips Healthcare, Cambridge, MA, USA) in 3 Tesla magnetic fields with echo times between 97.72 – 101.82 milliseconds. All scans have slice thicknesses of 2.5 mm, with 2.5 or 4 mm of space between slices. Sections are displayed in 512 x 512 pixel matrices and were reconstructed in 256 mm diameters.
DOI: 10.6084/m9.figshare.8035676.v1
title: Patient 4 CT

description: CTs and MRIs were both acquired under radiotherapy immobilization protocols with patients in the treatment position.<br>CT scans were acquired on one of four machine models (LightSpeed RT16, GE Medical Systems, Waukesha, WI, USA; Brilliance 64 or Brilliance Big Bore, Philips Healthcare, Cambridge, MA, USA; SOMATOM Definition Edge, Siemens, Washington D.C., USA) using x-ray tube currents between 208 – 434 mA at 120 kVp. All scans have slice thicknesses of either 2.5 or 3 mm, with 2.5 or 3 mm of space between slices. Sections are displayed in 512 x 512 pixel matrices and were reconstructed in diameters between 500 – 600 mm. <br>MRI scans were acquired in one of two machine models (Discovery MR750, GE Medical Systems, Waukesha, WI, USA; Ingenia, Philips Healthcare, Cambridge, MA, USA) in 3 Tesla magnetic fields with echo times between 97.72 – 101.82 milliseconds. All scans have slice thicknesses of 2.5 mm, with 2.5 or 4 mm of space between slices. Sections are displayed in 512 x 512 pixel matrices and were reconstructed in 256 mm diameters.
DOI: 10.6084/m9.figshare.8035658
title: Patient 2 CT

description: CTs and MRIs were both acquired under radiotherapy immobilization protocols with patients in the treatment position.<br>CT scans were acquired on one of four machine models (LightSpeed RT16, GE Medical Systems, Waukesha, WI, USA; Brilliance 64 or Brilliance Big Bore, Philips Healthcare, Cambridge, MA, USA; SOMATOM Definition Edge, Siemens, Washington D.C., USA) using x-ray tube currents between 208 – 434 mA at 120 kVp. All scans have slice thicknesses of either 2.5 or 3 mm, with 2.5 or 3 mm of space between slices. Sections are displayed in 512 x 512 pixel matrices and were reconstructed in diameters between 500 – 600 mm. <br>MRI scans were acquired in one of two machine models (Discovery MR750, GE Medical Systems, Waukesha, WI, USA; Ingenia, Philips Healthcare, Cambridge, MA, USA) in 3 Tesla magnetic fields with echo times between 97.72 – 101.82 milliseconds. All scans have slice thicknesses of 2.5 mm, with 2.5 or 4 mm of space between slices. Sections are displayed in 512 x 512 pixel matrices and were reconstructed in 256 mm diameters.
DOI: 10.6084/m9.figshare.8035667.v1
title: Patient 3 MRI

description: CTs and MRIs were both acquired under radiotherapy immobilization protocols with patients in the treatment position.<br>CT scans were acquired on one of four machine models (LightSpeed RT16, GE Medical Systems, Waukesha, WI, USA; Brilliance 64 or Brilliance Big Bore, Philips Healthcare, Cambridge, MA, USA; SOMATOM Definition Edge, Siemens, Washington D.C., USA) using x-ray tube currents between 208 – 434 mA at 120 kVp. All scans have slice thicknesses of either 2.5 or 3 mm, with 2.5 or 3 mm of space between slices. Sections are displayed in 512 x 512 pixel matrices and were reconstructed in diameters between 500 – 600 mm. <br>MRI scans were acquired in one of two machine models (Discovery MR750, GE Medical Systems, Waukesha, WI, USA; Ingenia, Philips Healthcare, Cambridge, MA, USA) in 3 Tesla magnetic fields with echo times between 97.72 – 101.82 milliseconds. All scans have slice thicknesses of 2.5 mm, with 2.5 or 4 mm of space between slices. Sections are displayed in 512 x 512 pixel matrices and were reconstructed in 256 mm diameters.
DOI: 10.6084/m9.figshare.8035652
title: Patient 2 MRI

description: CTs and MRIs were both acquired under radiotherapy immobilization protocols with patients in the treatment position.<br>CT scans were acquired on one of four machine models (LightSpeed RT16, GE Medical Systems, Waukesha, WI, USA; Brilliance 64 or Brilliance Big Bore, Philips Healthcare, Cambridge, MA, USA; SOMATOM Definition Edge, Siemens, Washington D.C., USA) using x-ray tube currents between 208 – 434 mA at 120 kVp. All scans have slice thicknesses of either 2.5 or 3 mm, with 2.5 or 3 mm of space between slices. Sections are displayed in 512 x 512 pixel matrices and were reconstructed in diameters between 500 – 600 mm. <br>MRI scans were acquired in one of two machine models (Discovery MR750, GE Medical Systems, Waukesha, WI, USA; Ingenia, Philips Healthcare, Cambridge, MA, USA) in 3 Tesla magnetic fields with echo times between 97.72 – 101.82 milliseconds. All scans have slice thicknesses of 2.5 mm, with 2.5 or 4 mm of space between slices. Sections are displayed in 512 x 512 pixel matrices and were reconstructed in 256 mm diameters.
DOI: 10.6084/m9.figshare.8035649
title: Patient 15 Structure Sets

description: Admire, Pinnacle, and Velocity denote structure sets after a deformable or rigid registration was applied to the MRI holding the CT as primary.
DOI: 10.6084/m9.figshare.8035658.v1
title: Patient 2 CT

description: CTs and MRIs were both acquired under radiotherapy immobilization protocols with patients in the treatment position.<br>CT scans were acquired on one of four machine models (LightSpeed RT16, GE Medical Systems, Waukesha, WI, USA; Brilliance 64 or Brilliance Big Bore, Philips Healthcare, Cambridge, MA, USA; SOMATOM Definition Edge, Siemens, Washington D.C., USA) using x-ray tube currents between 208 – 434 mA at 120 kVp. All scans have slice thicknesses of either 2.5 or 3 mm, with 2.5 or 3 mm of space between slices. Sections are displayed in 512 x 512 pixel matrices and were reconstructed in diameters between 500 – 600 mm. <br>MRI scans were acquired in one of two machine models (Discovery MR750, GE Medical Systems, Waukesha, WI, USA; Ingenia, Philips Healthcare, Cambridge, MA, USA) in 3 Tesla magnetic fields with echo times between 97.72 – 101.82 milliseconds. All scans have slice thicknesses of 2.5 mm, with 2.5 or 4 mm of space between slices. Sections are displayed in 512 x 512 pixel matrices and were reconstructed in 256 mm diameters.
DOI: 10.6084/m9.figshare.8035646
title: Patient 14 Structure Sets

description: Admire, Pinnacle, and Velocity denote structure sets after a deformable or rigid registration was applied to the MRI holding the CT as primary.
DOI: 10.6084/m9.figshare.8035643
title: Patient 13 Structure Sets

description: Admire, Pinnacle, and Velocity denote structure sets after a deformable or rigid registration was applied to the MRI holding the CT as primary.
DOI: 10.6084/m9.figshare.8035649.v1
title: Patient 15 Structure Sets

description: Admire, Pinnacle, and Velocity denote structure sets after a deformable or rigid registration was applied to the MRI holding the CT as primary.
DOI: 10.6084/m9.figshare.8035652.v1
title: Patient 2 MRI

description: CTs and MRIs were both acquired under radiotherapy immobilization protocols with patients in the treatment position.<br>CT scans were acquired on one of four machine models (LightSpeed RT16, GE Medical Systems, Waukesha, WI, USA; Brilliance 64 or Brilliance Big Bore, Philips Healthcare, Cambridge, MA, USA; SOMATOM Definition Edge, Siemens, Washington D.C., USA) using x-ray tube currents between 208 – 434 mA at 120 kVp. All scans have slice thicknesses of either 2.5 or 3 mm, with 2.5 or 3 mm of space between slices. Sections are displayed in 512 x 512 pixel matrices and were reconstructed in diameters between 500 – 600 mm. <br>MRI scans were acquired in one of two machine models (Discovery MR750, GE Medical Systems, Waukesha, WI, USA; Ingenia, Philips Healthcare, Cambridge, MA, USA) in 3 Tesla magnetic fields with echo times between 97.72 – 101.82 milliseconds. All scans have slice thicknesses of 2.5 mm, with 2.5 or 4 mm of space between slices. Sections are displayed in 512 x 512 pixel matrices and were reconstructed in 256 mm diameters.
DOI: 10.6084/m9.figshare.8035640
title: Patient 12 Structure Sets

description: Admire, Pinnacle, and Velocity denote structure sets after a deformable or rigid registration was applied to the MRI holding the CT as primary.
DOI: 10.6084/m9.figshare.8035646.v1
title: Patient 14 Structure Sets

description: Admire, Pinnacle, and Velocity denote structure sets after a deformable or rigid registration was applied to the MRI holding the CT as primary.
DOI: 10.6084/m9.figshare.8035628
title: Patient 11 Structure Sets

description: Admire, Pinnacle, and Velocity denote structure sets after a deformable or rigid registration was applied to the MRI holding the CT as primary.
DOI: 10.6084/m9.figshare.8035640.v1
title: Patient 12 Structure Sets

description: Admire, Pinnacle, and Velocity denote structure sets after a deformable or rigid registration was applied to the MRI holding the CT as primary.
DOI: 10.6084/m9.figshare.8035601
title: Patient 10 Structure Sets

description: Admire, Pinnacle, and Velocity denote structure sets after a deformable or rigid registration was applied to the MRI holding the CT as primary.
DOI: 10.6084/m9.figshare.8035595
title: Patient 9 Structure Sets

description: Admire, Pinnacle, and Velocity denote structure sets after a deformable or rigid registration was applied to the MRI holding the CT as primary.
DOI: 10.6084/m9.figshare.8035595.v1
title: Patient 9 Structure Sets

description: Admire, Pinnacle, and Velocity denote structure sets after a deformable or rigid registration was applied to the MRI holding the CT as primary.
DOI: 10.6084/m9.figshare.8035592
title: Patient 8 Structure Sets

description: Admire, Pinnacle, and Velocity denote structure sets after a deformable or rigid registration was applied to the MRI holding the CT as primary.
DOI: 10.6084/m9.figshare.8035583
title: Patient 6 Structure Sets

description: Admire, Pinnacle, and Velocity denote structure sets after a deformable or rigid registration was applied to the MRI holding the CT as primary.
DOI: 10.6084/m9.figshare.8035586
title: Patient 7 Structure Sets

description: Admire, Pinnacle, and Velocity denote structure sets after a deformable or rigid registration was applied to the MRI holding the CT as primary.
DOI: 10.6084/m9.figshare.8035583.v1
title: Patient 6 Structure Sets

description: Admire, Pinnacle, and Velocity denote structure sets after a deformable or rigid registration was applied to the MRI holding the CT as primary.
DOI: 10.6084/m9.figshare.8035580
title: Patient 5 Structure Sets

description: Admire, Pinnacle, and Velocity denote structure sets after a deformable or rigid registration was applied to the MRI holding the CT as primary.
DOI: 10.6084/m9.figshare.8035571
title: Patient 4 Structures Sets

description: Admire, Pinnacle, and Velocity denote structure sets after a deformable or rigid registration was applied to the MRI holding the CT as primary.
DOI: 10.6084/m9.figshare.8035574
title: JMJD3 and UTX Determine Fidelity and Lineage Specification of Human Neural Progenitor Cells

description: These data for investigating KDM6 (JMJD3 and/or UTX) function in human neurogenesis.
DOI: 10.6084/m9.figshare.8035586.v1
title: Patient 7 Structure Sets

description: Admire, Pinnacle, and Velocity denote structure sets after a deformable or rigid registration was applied to the MRI holding the CT as primary.
DOI: 10.6084/m9.figshare.8035568
title: Patient 3 Structure Sets

description: Admire, Pinnacle, and Velocity denote structure sets after a deformable or rigid registration was applied to the MRI holding the CT as primary.
DOI: 10.6084/m9.figshare.8035571.v1
title: Patient 4 Structures Sets

description: Admire, Pinnacle, and Velocity denote structure sets after a deformable or rigid registration was applied to the MRI holding the CT as primary.
DOI: 10.6084/m9.figshare.8035580.v1
title: Patient 5 Structure Sets

description: Admire, Pinnacle, and Velocity denote structure sets after a deformable or rigid registration was applied to the MRI holding the CT as primary.
DOI: 10.6084/m9.figshare.8035559
title: Patient 2 Structure Sets

description: Admire, Pinnacle, and Velocity denote structure sets after a deformable or rigid registration was applied to the MRI holding the CT as primary.
DOI: 10.6084/m9.figshare.8035568.v1
title: Patient 3 Structure Sets

description: Admire, Pinnacle, and Velocity denote structure sets after a deformable or rigid registration was applied to the MRI holding the CT as primary.
DOI: 10.6084/m9.figshare.8035559.v1
title: Patient 2 Structure Sets

description: Admire, Pinnacle, and Velocity denote structure sets after a deformable or rigid registration was applied to the MRI holding the CT as primary.
DOI: 10.6084/m9.figshare.8035535
title: BaMORC_figures.zip

description: Figures used in BaMORC publication.
DOI: 10.6084/m9.figshare.8035538
title: The stability of milk-based infant formulas during accelerated storage

description: The stability of milk-based formulas (infant formula and follow-up formula) were evaluated at 42°C and 50°C, during 90 days. Unsaturated fatty acids, color, peroxide values, headspace oxygen and volatile organic compounds (VOCs) were analyzed to evaluate the stability of milk-based formulas. No significant changes were observed in the unsaturated fatty acids (except DHA with a significant decrease after 90 days storage) of milk-based formulas stored at 42 or 50°C for 90 days. There is a significant change in color of the formulas during storage. For peroxide values and headspace oxygen, samples which were stored at a higher temperature would have higher peroxide values and less headspace oxygen after 90 days. For VOCs, results showed the significant differences of VOCs profiles in the formulas stored at different temperatures and lengths of storage period. In this study, the higher fat, the less oxidation stability was found.
DOI: 10.6084/m9.figshare.8035535.v1
title: BaMORC_figures.zip

description: Figures used in BaMORC publication.
DOI: 10.6084/m9.figshare.8035538.v1
title: The stability of milk-based infant formulas during accelerated storage

description: The stability of milk-based formulas (infant formula and follow-up formula) were evaluated at 42°C and 50°C, during 90 days. Unsaturated fatty acids, color, peroxide values, headspace oxygen and volatile organic compounds (VOCs) were analyzed to evaluate the stability of milk-based formulas. No significant changes were observed in the unsaturated fatty acids (except DHA with a significant decrease after 90 days storage) of milk-based formulas stored at 42 or 50°C for 90 days. There is a significant change in color of the formulas during storage. For peroxide values and headspace oxygen, samples which were stored at a higher temperature would have higher peroxide values and less headspace oxygen after 90 days. For VOCs, results showed the significant differences of VOCs profiles in the formulas stored at different temperatures and lengths of storage period. In this study, the higher fat, the less oxidation stability was found.
DOI: 10.6084/m9.figshare.8035388
title: Wigger stream temperatures

description: STREAM TEMPERATURE DATA COLLECTED IN THE RIVER WIGGER (SWITZERLAND)<br>Stream temperatures were measured at eleven sites at 15-min intervals by means of HOBO TidbiT v2 loggers. Two loggers per site were deployed.Sites' coordinates and acronyms are specified in SITES_COORDINATES.xlsx. Stream temperatures time series are split into three MS Excel spreadsheets:part 1: Jun 28, 2014 - Dec 31, 2015part 2: Jan 1, 2016 - Jun 30, 2017part 3: Jul 1, 2017 - Apr 23, 2019<br>Time format is GMT +02.Data collection started on Jun 28, 2014 and ended on April 23, 2019. Measurements in site 11 (LUT) started on Sep 29, 2015.Missing data are due to loss of loggers.<br>For further information, please refer to:Luca Carraro, Marco Toffolon, Enrico Bertuzzo, Andrea Rinaldo. SESTET: a Spatially-Explicit Stream Temperature model based on Equilibrium Temperature. Hydrological Processes, under review as of April 2019. <br>contact: Luca Carraro (luca.carraro@eawag.ch)
DOI: 10.6084/m9.figshare.8035235
title: Mobile_and_Stationary_Anemometer_Wind-SoutheasternSK_May2017.csv

description: A .csv file containing mobile and stationary anemometer measurements sampled along a square route with 12.8 km perimeter in Southeastern Saskatchewan, Canada. Mobile anemometer measurements of wind speed and wind direction were sampled at 1 Hz on public roads using a RM Young 86004 ultrasonic anemometer mounted on a 1.2 m tall mast above the cap of a 2016 Toyota Tacoma. The anemometer was positioned 0.5 m from the longitudinal axis of the truck on the driver’s side, and 0.3 m behind the start of the truck’s cap. Stationary anemometer measurements were collected using Decagon Device DS-2 sonic anemometers mounted at a height of 3 m above the ground. Measurements of time, wind speed, maximum gust, and direction were recorded with a Decagon Device Em50 datalogger in one minute intervals at the same time the mobile anemometer measurements were sampled. The GPS Coordinates of the Stationary Anemometers are Station 1 : N 49°26.678 W 103°49.350; Station 2: N 49°27.881 W 103°49.040; Station 3: N 49°27.762 W 103°46.664; Station 4: N 49°26.122 W 103°46.890. All sample times have been converted to Central Standard Time (CST). Wind speed and wind gust measurements are in km/h, and wind direction measurements are in degrees.
DOI: 10.6084/m9.figshare.8034887
title: Supplementary Material for: Systemic Treatment Options for Carcinoid Syndrome: A Systematic Review

description: <b><i>Background:</i></b> Carcinoid syndrome symptoms significantly reduce quality of life in patients with neuroendocrine tumors. Evidence supporting the use of somatostatin analogues in carcinoid syndrome symptom control dates back 30 years. The introduction of new treatment options for carcinoid syndrome, such as telotristat ethyl in 2017, highlights the need for a review of high-level evidence of new and established systemic treatments. <b><i>Objective:</i></b> To examine the efficacy and safety of systemic treatment options for patients with carcinoid syndrome. <b><i>Method:</i></b> A systematic review of English language articles was conducted using PubMed, EMBASE, and the Cochrane Controlled Trials Register using the search terms carcinoid syndrome, clinical trial, clinical study, and prospective study. Additional studies were identified by searching abstracts from oncology or neuroendocrine tumor congresses during the previous year. Prospective, interventional, phase II or III clinical trials or pivotal trials leading to drug approval were included. Studies were required to have &gt;85% of patients with carcinoid syndrome; secondary publications were excluded. <b><i>Results:</i></b> The search identified 233 unique records, of which 12 trials met the criteria for inclusion. Interventions assessed in these trials included short-acting and long-acting octreotide, lanreotide prolonged-release and autogel/depot, short-acting and long-acting pasireotide, telotristat ethyl, everolimus, and peptide receptor radionuclide therapy. Somatostatin analogues provided substantial symptom relief for patients with carcinoid syndrome. For refractory symptoms, an increased dose of somatostatin analogue or addition of telotristat ethyl were valuable options. Interventions were generally well tolerated, with few serious treatment-related adverse events. <b><i>Conclusions:</i></b> By critically evaluating high-level evidence in a rigorous manner, this review highlights the general lack of consensus regarding what defines symptom control in studies of carcinoid syndrome and the need for standardized treatment guidelines for this disease. More prospective trials of treatments for carcinoid syndrome are warranted to assist oncologists with optimizing treatment selection and sequencing in this patient population.